Information Provided By:
Fly News Breaks for March 1, 2019
APTO
Mar 1, 2019 | 09:09 EDT
RBC Capital analyst Gregory Renza started Aptose Biosciences with an Outperform rating and $6 price target, stating that he believes key asset CG-806 has a "promising profile and solid pre-clinical data" in targeted oncology.